IGM Biosciences Inc (IGMS) - Total Assets
Based on the latest financial reports, IGM Biosciences Inc (IGMS) holds total assets worth $106.99 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check IGM Biosciences Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
IGM Biosciences Inc - Total Assets Trend (2017–2024)
This chart illustrates how IGM Biosciences Inc's total assets have evolved over time, based on quarterly financial data. Explore IGM Biosciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
IGM Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
IGM Biosciences Inc's total assets of $106.99 Million consist of 72.9% current assets and 27.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 10.0% |
| Accounts Receivable | $800.00K | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how IGM Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IGM Biosciences Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: IGM Biosciences Inc's current assets represent 72.9% of total assets in 2024, an increase from 47.1% in 2017.
- Cash Position: Cash and equivalents constituted 10.0% of total assets in 2024, down from 31.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
IGM Biosciences Inc Competitors by Total Assets
Key competitors of IGM Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
IGM Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 17.66 | 7.06 | 13.90 |
| Quick Ratio | 17.66 | 7.06 | 13.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $100.93 Million | $228.36 Million | $171.37 Million |
IGM Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between IGM Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.76 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -37.2% |
| Total Assets | $265.71 Million |
| Market Capitalization | $46.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values IGM Biosciences Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: IGM Biosciences Inc's assets decreased by 37.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for IGM Biosciences Inc (2017–2024)
The table below shows the annual total assets of IGM Biosciences Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $265.71 Million | -37.24% |
| 2023-12-31 | $423.41 Million | -17.54% |
| 2022-12-31 | $513.50 Million | +72.24% |
| 2021-12-31 | $298.13 Million | -27.04% |
| 2020-12-31 | $408.63 Million | +56.35% |
| 2019-12-31 | $261.35 Million | +6468.23% |
| 2018-12-31 | $3.98 Million | +186.26% |
| 2017-12-31 | $1.39 Million | -- |
About IGM Biosciences Inc
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer and autoimmune and inflammatory diseases. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. As of August 14, 2025, IGM Biosciences, In… Read more